Eli Lilly partners with ABL Biotech on bispecific antibodies via the Grabody platform in a deal worth up to $2.6B. Read more ...

Novo Nordisk A/S faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy. Learn more ...

The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull ...

Trump announced popular weight loss treatments would be offered directly on a new “TrumpRx.gov” website at lower prices.

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

US accounts for 72.7% of the MSCI World Index, compared with just 2.6% for Europe’s biggest stock market, France ...